3,5-dimethoxy-1-(2-methyl-7-phenoxyheptan-2-yl)benzene | 1605280-99-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-dimethoxy-1-(2-methyl-7-phenoxyheptan-2-yl)benzene
• 英文别名: 1,3-dimethoxy-5-(2-methyl-7-phenoxyheptan-2-yl)benzene；1,3-Dimethoxy-5-(2-methyl-7-phenoxyheptan-2-yl)benzene
• CAS: 1605280-99-6
• 化学式: C₂₂H₃₀O₃
• 分子量: 342.478
• InChiKey: ANQWSKNMPAEISW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  25
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,5-dimethoxy-1-(2-methyl-7-phenoxyheptan-2-yl)benzene 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以99%的产率得到5-(7-bromo-2-methylhept-2-yl)resorcinol
  参考文献：
  名称：

  Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures

  摘要：

  Human endocannabinoid systems modulate multiple physiological processes mainly through the activation of cannabinoid receptors CB1 and CB2. Their high sequence similarity, low agonist selectivity, and lack of activation and G protein-coupling knowledge have hindered the development of therapeutic applications. Importantly, missing structural information has significantly held back the development of promising CB2-selective agonist drugs for treating inflammatory and neuropathic pain without the psychoactivity of CB1. Here, we report the cryoelectron microscopy structures of synthetic cannabinoid-bound CB2 and CB1 in complex with G(i), as well as agonist-bound CB2 crystal structure. Of important scientific and therapeutic benefit, our results reveal a diverse activation and signaling mechanism, the structural basis of CB2-selective agonists design, and the unexpected interaction of cholesterol with CB1, suggestive of its endogenous allosteric modulating role.

  DOI：

  10.1016/j.cell.2020.01.008
• 作为产物：
  描述：

  2-(3,5-dimethoxyphenyl)-2-methylpropanal 在 palladium on activated charcoal 、 氢气 、 双(三甲基硅烷基)氨基钾 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 反应 3.33h， 生成 3,5-dimethoxy-1-(2-methyl-7-phenoxyheptan-2-yl)benzene
  参考文献：
  名称：

  Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures

  摘要：

  Human endocannabinoid systems modulate multiple physiological processes mainly through the activation of cannabinoid receptors CB1 and CB2. Their high sequence similarity, low agonist selectivity, and lack of activation and G protein-coupling knowledge have hindered the development of therapeutic applications. Importantly, missing structural information has significantly held back the development of promising CB2-selective agonist drugs for treating inflammatory and neuropathic pain without the psychoactivity of CB1. Here, we report the cryoelectron microscopy structures of synthetic cannabinoid-bound CB2 and CB1 in complex with G(i), as well as agonist-bound CB2 crystal structure. Of important scientific and therapeutic benefit, our results reveal a diverse activation and signaling mechanism, the structural basis of CB2-selective agonists design, and the unexpected interaction of cholesterol with CB1, suggestive of its endogenous allosteric modulating role.

  DOI：

  10.1016/j.cell.2020.01.008

文献信息

• [EN] 2-CYCLOALKYL RESORCINOL CANNABINERGIC LIGANDS<br/>[FR] LIGANDS CANNABINERGIQUES DE 2-CYCLOALKYL RÉSORCINOL
  申请人：UNIV NORTHEASTERN

  公开号：WO2014062965A1

  公开（公告）日：2014-04-24

  The present invention relates to novel 2-cycloalkyl resorcinol compounds; to pharmaceutical compositions comprising the compounds; and to methods of preparing the compounds and uses thereof. The disclosed compounds can bind to and modulate the cannabinoid receptors and thus, they are specific ligands for these receptors. The invented compounds, when administered in a therapeutically effective amount to an individual or animal, results in a sufficiently high level of that compound in the individual or animal to cause a physiological response. The physiological response may be useful to treat a number of physiological conditions.

  本发明涉及新型2-环烷基间苯二酚化合物；包括这些化合物的药物组合物；以及制备这些化合物和它们的用途的方法。所披露的化合物可以结合并调节大麻素受体，因此它们是这些受体的特异性配体。当将这些发明的化合物以治疗有效剂量的方式给予个体或动物时，会在个体或动物体内产生足够高水平的该化合物，从而引起生理反应。这种生理反应可能有助于治疗多种生理状况。
• Synthesis of Functionalized Cannabilactones
  作者：Yingpeng Liu、Thanh C. Ho、Mohammed Baradwan、Maria Pascual Lopez-Alberca、Christos Iliopoulos-Tsoutsouvas、Spyros P. Nikas、Alexandros Makriyannis

  DOI：10.3390/molecules25030684

  日期：——

  A new approach to synthesize cannabilactones using Suzuki cross-coupling reaction followed by one-step demethylation-cyclization is presented. The two key cannabilactone prototypes AM1710 and AM1714 were obtained selectively in high overall yields and in a lesser number of synthetic steps when compared to our earlier synthesis. The new approach expedited the synthesis of cannabilactone analogs with structural modifications at the four potential pharmacophoric regions.

  使用Suzuki交叉偶联反应后跟一步脱甲基环化合成卡纳比拉克酮的新方法被提出。与我们之前的合成相比，两种关键的卡纳比拉克酮原型AM1710和AM1714以更高的总收率和更少的合成步骤被选择性地获得。这种新方法加速了在四个潜在的药效团区域进行结构修改的卡纳比拉克酮类似物的合成。
• 2-CYCLOALKYL RESORCINOL CANNABINERGIC LIGANDS
  申请人：NORTHEASTERN UNIVERSITY

  公开号：US20150274623A1

  公开（公告）日：2015-10-01

  The present invention relates to novel 2-cycloalkyl resorcinol compounds; to pharmaceutical compositions comprising the compounds; and to methods of preparing the compounds and uses thereof. The disclosed compounds can bind to and modulate the cannabinoid receptors and thus, they are specific ligands for these receptors. The invented compounds, when administered in a therapeutically effective amount to an individual or animal, results in a sufficiently high level of that compound in the individual or animal to cause a physiological response. The physiological response may be useful to treat a number of physiological conditions.

  本发明涉及一种新型的2-环烷基邻苯二酚化合物；涉及含有该化合物的药物组合物；以及制备该化合物和使用该化合物的方法。所披露的化合物能够结合和调节大麻素受体，因此它们是这些受体的特异性配体。当以治疗有效量的方式给予这些发明化合物给个体或动物时，会在个体或动物中产生足够高的该化合物水平以引起生理反应。这种生理反应可能有助于治疗许多生理状况。
• US9517989B2
  申请人：——

  公开号：US9517989B2

  公开（公告）日：2016-12-13
• Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures
  作者：Tian Hua、Xiaoting Li、Lijie Wu、Christos Iliopoulos-Tsoutsouvas、Yuxia Wang、Meng Wu、Ling Shen、Christina A. Brust、Spyros P. Nikas、Feng Song、Xiyong Song、Shuguang Yuan、Qianqian Sun、Yiran Wu、Shan Jiang、Travis W. Grim、Othman Benchama、Edward L. Stahl、Nikolai Zvonok、Suwen Zhao、Laura M. Bohn、Alexandros Makriyannis、Zhi-Jie Liu

  DOI：10.1016/j.cell.2020.01.008

  日期：2020.2

  Human endocannabinoid systems modulate multiple physiological processes mainly through the activation of cannabinoid receptors CB1 and CB2. Their high sequence similarity, low agonist selectivity, and lack of activation and G protein-coupling knowledge have hindered the development of therapeutic applications. Importantly, missing structural information has significantly held back the development of promising CB2-selective agonist drugs for treating inflammatory and neuropathic pain without the psychoactivity of CB1. Here, we report the cryoelectron microscopy structures of synthetic cannabinoid-bound CB2 and CB1 in complex with G(i), as well as agonist-bound CB2 crystal structure. Of important scientific and therapeutic benefit, our results reveal a diverse activation and signaling mechanism, the structural basis of CB2-selective agonists design, and the unexpected interaction of cholesterol with CB1, suggestive of its endogenous allosteric modulating role.